Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TREST.
TESTOSTERONE ENANTHATE vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
50-400 mg intramuscularly every 2-4 weeks
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category D/X
Category C
Androgen
Androgen